These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21717480)

  • 1. Molecular dynamics simulation reveals structural and thermodynamic features of kinase activation by cancer mutations within the epidermal growth factor receptor.
    Wan S; Coveney PV
    J Comput Chem; 2011 Oct; 32(13):2843-52. PubMed ID: 21717480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation.
    Papakyriakou A; Vourloumis D; Tzortzatou-Stathopoulou F; Karpusas M
    Proteins; 2009 Aug; 76(2):375-86. PubMed ID: 19173306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
    Holbrook MR; Slakey LL; Gross DJ
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
    Park J; McDonald JJ; Petter RC; Houk KN
    J Chem Theory Comput; 2016 Apr; 12(4):2066-78. PubMed ID: 27010480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study.
    Mustafa M; Mirza A; Kannan N
    Proteins; 2011 Jan; 79(1):99-114. PubMed ID: 20938978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
    Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
    Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
    Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
    Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
    Kancha RK; von Bubnoff N; Peschel C; Duyster J
    Clin Cancer Res; 2009 Jan; 15(2):460-7. PubMed ID: 19147750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.
    Schiffer HH; Reding EC; Fuhs SR; Lu Q; Piu F; Wong S; Littler PL; Weiner DM; Keefe W; Tan PK; Nash NR; Knapp AE; Olsson R; Brann MR
    Mol Pharmacol; 2007 Feb; 71(2):508-18. PubMed ID: 16968809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
    Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
    Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Johnson BE; Jänne PA
    Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
    Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
    Shan Y; Eastwood MP; Zhang X; Kim ET; Arkhipov A; Dror RO; Jumper J; Kuriyan J; Shaw DE
    Cell; 2012 May; 149(4):860-70. PubMed ID: 22579287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
    Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
    Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.